(Reuters) – Britain’s competition watchdog said Theramex’s purchase of European rights to two of Viatris’ women’s healthcare products ranges could lead to higher prices and lesser options for hormone replacement therapy treatments.
Drugmaker Viatris agreed to sell its rights to Duphaston and Femoston product ranges to London-based Theramex in October.
(Reporting by Prerna Bedi in Bengaluru; Editing by Shinjini Ganguli)
Comments